Lack of evidence for the efficacy of memantine in mild Alzheimer disease

Lon S Schneider, Karen S Dagerman, Julian P T Higgins, Rupert McShane

Research output: Contribution to journalArticle (Academic Journal)

179 Citations (Scopus)

Abstract

We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD). Memantine is indicated in the United States and Europe for moderate to severe AD, which is diagnosed if a patient has a Mini-Mental State Examination (MMSE) score of less than 15 or less than 20, respectively. Yet memantine is very frequently prescribed for mild AD and mild cognitive impairment, and a manufacturer-sponsored meta-analysis claimed its efficacy in mild AD.
Original languageEnglish
Pages (from-to)991-8
Number of pages8
JournalArchives of Neurology
Volume68
Issue number8
DOIs
Publication statusPublished - 2011

Fingerprint Dive into the research topics of 'Lack of evidence for the efficacy of memantine in mild Alzheimer disease'. Together they form a unique fingerprint.

Cite this